ViroPharma Incorporated, a pharmaceutical company, develops and sells drugs that address serious diseases treated by physician specialists and in hospital settings. The company focuses on product development activities on virus and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. ViroPharma is a member of the NASDAQ Biotechnology Index and the S&P 600.
The report provides a comprehensive study of the Viropharma’s patent portfolio, highlighting the following points:
Company patent portfolio evolution
Countries of deposition and patents’ origin
Legal status of patent filings
New trends and emerging topics
Reasons to Buy :
Enhance your understanding of Viropharma’s IP strategy.
Assess the growth potential of Viropharma in its therapy areas of focus.
Exploit collaboration opportunities with Viropharma